Anti-infective Drug Discovery

Innovation in antibiotics is declining during the last years, turning this market into a generic battlefield of high-volumes & small margins sales. Nevertheless, patients are still suffering from difficult infections which result in high costs for the healthcare system. Such infections are very often linked to the presence of biofilms that reduce the efficacy of classical antibiotics.

At BioFilm Control we have developed the technology and the service that will make the difference:

We show how classical antibiotics are inefficient to prevent the formation of biofilms even when they inhibit planktonic growth
We use our technology to perform high throughput mode screens of large sets of molecules to discover compounds that are efficient inhibitors of biofilm formation
We are also deploying innovative approaches to find new sources of molecules and enzymes

Thanks to our unique technological offers, focusing on the biofilm aspects of bacterial infections opens new routes to innovative treatments that have the potential to be marketed at premium prices.

Learn more about how our service and technology can accompany your quest of performance,